Mirada Medical is a world leading medical imaging software company providing simple and accessible solutions to complex image analysis problems in the diagnosis and treatment of cancer. Mirada’s products are available globally under its own brand, and on an OEM basis through a select number of blue-chip healthcare companies.
Incidence of cancer is expected to increase globally by 62% by 2040. Mirada’s technologies increase the speed and accuracy of cancer treatment and diagnosis, not only helping clinicians be more effective but also improving cancer care.
Mirada has a long track record of success in medical imaging software with a global installed base of ~2,000 hospitals and partnerships with the leading global medical equipment companies and therefore benefits from strong market recognition and reputation.
Apposite investment will enable Mirada to accelerate product development and strengthen market accessibility of its AI-based software applications and in particular of its latest Deep Learning Contouring radiotherapy treatment planning solution, DLCExpert™, the first product of its kind to receive FDA clearance.